Antisence oligonucleotides to c-myb proto-oncogene and uses ther

Details Antisence oligonucleotides to c-myb proto-oncogene and uses ther Antisence oligonucleotides to c-myb proto-oncogene and uses ther

1989-10-27

1992-03-24

Brown, Johnnie R.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 27, 536 28, 536 29, 435 6, 935 78, A61K 3170, C07H 2100

Patent

active

050988905

ABSTRACT:
Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-myb gene. These "antisense" oligonucleotides are hybridizable to the c-myb mRNA transcript. Such oligonucleotides are useful in treating hematologic neoplasms and in inducing immunosuppression. They are particularly useful as bone marrow purging agents.

REFERENCES:
patent: 4689320 (1987-06-01), Kaji
Majello et al., Proc. Natl. Acad. Sci. U.S.A. 83, 9636-9640 (1986).
Westin et al., Proc. Natl. Acad. Sci. U.S.A. 79, 2194 (1982).
Duprey et al., Proc. Natl. Acad. Sci. U.S.A. 82, 6937 (1985).
Clarke et al., Molecular and Cellular Physiology 8, 884-892 (Feb. 1988).
Slamon et al., Science 233, 347 (1986).
Wickstrom et al., Proc. Natl. Acad. Sci. U.S.A. 85, 1028-1032 (Feb. 1988).
Loke et al., Clin. Res. 36(3), 443A (abstract) 1988.
Holt et al., Mol. Cell. Biol. 8, 963-973 (Feb. 1988).
Yakoyama et al., Proc. Natl. Acad. Sci. U.S.A. 84, 7363-7367 (Nov. 1987).
Harel-Bellan et al., J. Immunol. 140, 2431-2435 (Apr. 1988).
Harel-Bellan et al., J. Cell. Biochem. Supplement 12A, 167 (Jan. 1988).
Nishikura et al., Mol. Cell. Biol. 7, 639-649 (Feb. 1987).
Nishikura et al., J. Cell. Biochem. Supplement 11A-D, 146 (1987).
Riabowol et al., Mol. Cell. Biol. 8, 1670-1676 (Apr. 1988).
Mercola et al., Biochem. Biophys. Res. Comm. 147, 288-294 (Aug. 1987).
Groger et al., Proceedings American Assn. for Cancer Research 29, 439 (Mar. 1988).
Shohat et al., Oncogene, 1, 277-283 (1987).
Penno et al., American Journal of Human Genetics 39(3) Supplement, A38 (1986).
Reed et al., J. Cell. Biochem. Supplement 12A, 172 (Jan. 1988).
Weintraub et al., TIG, Jan. 1985, pp. 22-25.
Jaskulski et al., Science 240, 1544-46 (1988).
Paoletti, Anti-Cancer Drug Design 2, 325-331 (1988).
Anfossi et al., Clin. Res. 37l, 376A (abstract) (Apr. 1989).
Anfossi et al, Proc. Natl. Acad. Sci. U.S.A. 86, 3379-3383 (May 1989).
Gewirtz et al., Science 245, 180-183 (Jul. 14, 1989).
Caracciolo et al., Science 245, 1107-1110 (Sep. 8, 1989).
Daouk et al., J. Biol. Chem., 263(6), 2442-2446 (1988).
Mariman et al., Genomics, 1, 126-137 (1987).

Affiliated with

Also associated with

Rating

Antisence oligonucleotides to c-myb proto-oncogene and uses ther does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisence oligonucleotides to c-myb proto-oncogene and uses ther, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisence oligonucleotides to c-myb proto-oncogene and uses ther will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2010291